LGALS3 and hepatocellular carcinoma: However, genetically engineered to overexpress LGALS3 in HCC cells abrogated the inhibitory effect of verteporfin on skeletal complications of HCC (Figure 8A,B and Figure S7B–F, Supporting Information), which further supported the essential role of LGALS3 in HCC‐BM.